double-blind trial tamoxifen prednisolone versus tamoxifen placebo postmenopausal women metastatic breast cancer collaborative trial North Central Cancer Treatment Group Mayo Clinic trial superiority tamoxifen TAM prednisolone PRDLN TAM postmenopausal women metastatic breast cancer total patients double-blind trial TAM mg placebo TAM PRDLN mg patients patients measurable evaluable disease objective responses TAM patients TAM PRDLN patients chi-square patients median time progression months TAM months TAM PRDLN log rank median survival time months Covariate significant association treatment outcome Weight gain edema TAM PRDLN addition PRDLN TAM management postmenopausal women metastatic breast cancer 